Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual pati...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Proteomes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-7382/9/4/42 |
| _version_ | 1797501107945078784 |
|---|---|
| author | Paul Dowling Ciara Tierney Katie Dunphy Juho J. Miettinen Caroline A. Heckman Despina Bazou Peter O’Gorman |
| author_facet | Paul Dowling Ciara Tierney Katie Dunphy Juho J. Miettinen Caroline A. Heckman Despina Bazou Peter O’Gorman |
| author_sort | Paul Dowling |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions. |
| first_indexed | 2024-03-10T03:13:35Z |
| format | Article |
| id | doaj.art-6849e7a2dbd34a158d0fc5706886522a |
| institution | Directory Open Access Journal |
| issn | 2227-7382 |
| language | English |
| last_indexed | 2024-03-10T03:13:35Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proteomes |
| spelling | doaj.art-6849e7a2dbd34a158d0fc5706886522a2023-11-23T10:20:01ZengMDPI AGProteomes2227-73822021-10-01944210.3390/proteomes9040042Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted ApproachesPaul Dowling0Ciara Tierney1Katie Dunphy2Juho J. Miettinen3Caroline A. Heckman4Despina Bazou5Peter O’Gorman6Department of Biology, Maynooth University, W23 F2H6 Maynooth, IrelandDepartment of Biology, Maynooth University, W23 F2H6 Maynooth, IrelandDepartment of Biology, Maynooth University, W23 F2H6 Maynooth, IrelandInstitute for Molecular Medicine Finland—FIMM, HiLIFE—Helsinki Institute of Life Science, iCAN Digital Cancer Medicine Flagship, University of Helsinki, FI-00014 Helsinki, FinlandInstitute for Molecular Medicine Finland—FIMM, HiLIFE—Helsinki Institute of Life Science, iCAN Digital Cancer Medicine Flagship, University of Helsinki, FI-00014 Helsinki, FinlandDepartment of Haematology, Mater Misericordiae University Hospital, D07 KH4C Dublin, IrelandDepartment of Haematology, Mater Misericordiae University Hospital, D07 KH4C Dublin, IrelandAcute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions.https://www.mdpi.com/2227-7382/9/4/42acute myeloid leukemiabiomarkersimmunoassaymass spectrometryproteomics |
| spellingShingle | Paul Dowling Ciara Tierney Katie Dunphy Juho J. Miettinen Caroline A. Heckman Despina Bazou Peter O’Gorman Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches Proteomes acute myeloid leukemia biomarkers immunoassay mass spectrometry proteomics |
| title | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches |
| title_full | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches |
| title_fullStr | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches |
| title_full_unstemmed | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches |
| title_short | Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches |
| title_sort | identification of protein biomarker signatures for acute myeloid leukemia aml using both nontargeted and targeted approaches |
| topic | acute myeloid leukemia biomarkers immunoassay mass spectrometry proteomics |
| url | https://www.mdpi.com/2227-7382/9/4/42 |
| work_keys_str_mv | AT pauldowling identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT ciaratierney identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT katiedunphy identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT juhojmiettinen identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT carolineaheckman identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT despinabazou identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches AT peterogorman identificationofproteinbiomarkersignaturesforacutemyeloidleukemiaamlusingbothnontargetedandtargetedapproaches |